Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC)

Authors

• A Basu Mallick

Publication/Presentation Date

6-2022

Volume

33

Issue

4

First Page

294

Last Page

294

Published In/Presented At

https://doi.org/10.1016/j.annonc.2022.04.215

Disciplines

Medicine and Health Sciences

Department(s)

Hematology-Medical Oncology Division

Document Type

Article